The long established notion that UV irradiation is always harmful to patients with systemic lupus erythematosus has been challenged by some recent reports of benefit using a form of phototherapy with UV-A,. In the review we discuss the different types of UV radiation, the links between certain forms of such radiation and clinical manifestations and consider the mechanisms involved.
CLINICAL EFFECTS
Typically, clinical investigation of photosensitivity is performed by phototesting small areas of skin with UV radiation. Most studies of SLE have examined the effects of UV-B radiation, with 30-50% of patients developing a skin reaction upon phototesting [12] [13] [14] . Systemic disease is induced rarely, perhaps due to the small area of irradiation. Patients with a UV-B-invoked reaction develop erythema at the phototest site 24 h-3 weeks after irradiation, and this can persist for weeks [15, 16] . Although UV-A may exacerbate skin disease, some studies report no effect [12, 14, 15, [17] [18] [19] . In a study of 20 patients with SLE, characteristic lesions were reproduced in a quarter of those irradiated, mainly with UV-B or UV-B with UV-A, but in one patient with UV-A alone [14] . Moreover, a history of photosensitivity does not necessarily predict positive reactions on phototesting. One-third of patients with SLE will have no phototest reaction despite a history of photosensitivity, whereas positive phototests may occur in patients with no previous photosensitivity [14] .
PATHOGENESIS OF PHOTOSENSITIVITY
Amongst the mechanisms that may determine photosensitivity following UV irradiation, circulating antibodies to the Ro/SSA antigen [ribonucleoprotein (RNP) particles linked to particular small cytoplasmic RNA species] have been associated with photoinduced lesions and may confer an increased risk compared to other antibodies [20, 21] . There is no difference, however, in the frequency of antibodies to Ro/SSA among patients with positive and negative phototest reactions [15, 18, 21] . Photosensitivity is diagnostic for SCLE and 75% of patients have antibodies to Ro/SSA antigen, although titres do not correlate with skin activity [22] [23] [24] . This strong association of Ro/SSA antibody in SCLE has served as a model for investigation of the immunopathogenic mechanism of photosensitivity [25] . In human skin grafted onto nude mice, injection of sera having anti-Ro/SSA antibodies, but not anti-DNA antibodies, resulted in Ro antibody deposition in the skin [26, 27] . UV-B, but not UV-A, increases the expression and binding of autoantibody to Ro/SSA and, to a lesser extent, RNP and Sm antigens, but not to DNA, while concomitant radiation of UV-B with UV-A appears to have no effect on binding [28] [29] [30] , In contrast, UV-B-irradiated keratinocytes from patients with SLE show no association of in vitro photosensitivity with a clinical history of photosensitivity or anti-Ro/SSA antibodies [29] .
Laboratory studies support a mechanism by which anti-Ro/SSA antibodies might recognize the normally intracellular antigen in epidermal cells [25] . Thus, following UV-B irradiation, keratinocytes become apoptotic with Ro/SSA antigen expression in discrete surface blebs which appear to be associated with sites of oxygen modification [31] . Photoinduced epidermal damage is likely to occur as a result of antibody-dependent cell-mediated cytotoxicity (ADCC) after autoantibody binding to Ro/SSA antigen, whereby effector cell attachment to the Fc receptor of the Ro/SSA antibody on keratinocytes results in cell lysis [32] . Indeed, destruction of basal keratinocytes, those above the dermal-epidermal junction, is a consistent finding in cutaneous lupus and may be particularly prominent in SCLE [32] [33] [34] .
With the current knowledge that Ro/SSA exists in several forms, the question of the precise specificity of anti-Ro antibody in this context would be well worth examining. Ro/SSA antigen is a system of multiple polypeptides with different binding properties, and these differ among cell types. The 60 kDa Ro/SSA antigen has binding sites for RNA and DNA, and may play a role in transcriptional regulation, while the 52 kDa antigen may be a DNA-binding protein [35] . Clinically, high-titre antibodies to 60 kDa Ro/SSA antigen have been demonstrated in SCLE patients, while anti-52 kDa Ro/SSA antibodies occurred only in association with the anti-60 kDa antigen [36] . No increase in 52 or 60 kDa antigen, however, has been reported after UV-B irradiation of keratinocytes, but rather, a selective expression of calreticulin, a 46 kDa peptide bound by some anti-Ro antibodies [37] .
Yet Ro/SSA antibodies may not be necessary for cutaneous damage, particularly in other forms of photosensitive lupus with predominantly dermal rather than epidermal damage [16, 25] . UV irradiation triggers TNF-a, IL-1 and IL-6 release, resulting in local inflammation and enhancing ICAM-1 expression on keratinocytes which, in turn, may facilitate cellular interaction, recognition and subsequent cytotoxicity [25, [38] [39] [40] . Similarly, UV irradiation increases E-selectin in dermal endothelial cells which may promote migration of memory and activated T cells [41] . Members of the heat shock protein (hsp) 70 family, 72 kDa and 70 kDa proteins, are increased by UV radiation [42, 43] . These proteins may serve as molecular chaperonins with a role in Ro/SSA translocation, although overexpression of hsp 70 decreases UV-induced IL-1 and IL-6 release, and increases cell viability after UV-B irradiation [43] . While prostaglandin production and release may be enhanced by UV light, UV-irradiated antibodies to Ro/SSA may contribute to changes in vascular dilatation and may increase blood flow [44, 45] .
Unlike cutaneous photosensitivity, the pathogenesis of systemic photosensitivity is not clearly understood, and may be due to causes other than Ro/SSA autoantibody and ADCC (Fig. 2) . In contrast to Ro/SSA antigen-antibody binding, the binding of anti-DNA antibodies to DNA is not increased after UV-A or UV-B irradiation [46] . UV-B radiation induces thymine dimers as products of DNA damage, while UV-A induces single-strand DNA breaks [47, 48] . Antibodies to UV-altered DNA (UV-DNA) are increased in sera of patients with SLE compared with normal controls, but again this does not correlate with a history of photosensitivity [49, 50] . Interestingly, i.v. injection of UV-DNA can result in glomerulonephritis (GN) in New Zealand albino rabbits with anti-DNA glomerular deposition [51] . Effects of direct UV irradiation on animal models of SLE are variable, although generally there is increased morbidity and antibody production [52] . Furthermore, UV effects on cutaneous immune function may contribute to systemic photosensitivity. UV-induced cytokine production by keratinocytes may result in systemic inflammation, while UV-B can activate a skin-derived mediator, cLs-urocanic acid, which results in profound suppression of systemic cell-mediated immunity [53] . UV-B may affect Langerhans cells (LC) in several ways, e.g. by decreasing the number of these cells or changing their morphology and function, and decreasing their ability to stimulate T cells, particularly CD4 + Thl, thus resulting in unopposed Th2 cell stimulation of B cells [54, 55] . In addition, UV-B-irradiated epidermal macrophages activate CD4 + CD45RA + suppressor-inducer cells which results in a predominantly suppressor effector T-cell response in circulating lymphocytes [56] .
That UV-A has different photobiological effects than UV-B may be significant in systemic photosensitivity (Table I) . Unlike UV-B, UB-A penetrates the dermis and dermal vasculature, and may have a more direct effect on systemic immunity. Although lymphocytes cultured from patients with SLE showed increased susceptibility to UV-B irradiation as well as decreased DNA repair synthesis, UV-A had either no effect or increased DNA repair synthesis [57] . Although UV-B may be more efficient in causing damage to DNA through direct absorption, UV-A has little effect on DNA without sensitization or activation of a secondary molecule ('chromophore') which forms a DNA cross-linking agent that may inhibit lymphocyte proliferation [7] . In skin as well as in lymphocytes, chromophore action is partly mediated by activated oxygen species which may contribute to damage of cell membranes or DNA [7, 58, 59] . Splenocytes from SLE murine models appear to be more sensitive to UV-A-induced oxidative stress than normal splenocytes [8, 9] . Interestingly, pre-irradiation of skin fibroblasts with UV-A results in decreased oxidative 
Role of Oi radical damage
Antioxidant response DNA repair synthesis UV-A dermis mixed no effect no effect no effect (UV-A,) no effect (UV-A,) no effect minimal without chromophore + + + membrane damage upon subsequent UV-A exposure, and haem oxygenase 1 and ferritin may mediate this adaptive response [60] .
THE BASIS OF PHOTOTHERAPY
The principle of chromophore activation is the basis of photochemotherapy, and has been used in the investigation and treatment of SLE. Photochemotherapy induces an autoregulatory response in the recipient that may deactivate abnormal T-cell idiotypes and alter T-cell receptor specificity [61] [62] [63] . Modification of lymphocyte function with UV-A-activated psoralens (PUVA) is the most common form of photochemotherapy, but requires direct skin irradiation.
Most intriguing is that UV-A alone may be beneficial without a known chromophore. UV-A irradiation of (NZB x NZW)F| mice resulted in increased survival and decreased circulating anti-DNA antibodies [64] . A mechanism for the beneficial effect of UV-A is unclear, although it may be due to the absence of a chromophore and subsequent lack of effect on DNA. Furthermore, longer wavelengths of UV-A, UV-A, (340-400 nm), do not affect LC function, perhaps resulting in decreased stimulation of B-cell function [65] .
EFFECTS OF PHOTOTHERAPY
In SLE, extracorporeal photochemotherapy (photopheresis) has been used in order to avoid potentially harmful effects of direct light exposure. Photopheresis of MRL/1 mice and a murine model of lupus-like graft-versus-host disease resulted in delayed progression of autoimmune disease [63, 66] . In an uncontrolled trial of photopheresis in eight patients with SLE, seven had significant clinical improvement, including decreased joint scores, improved skin lesions, and minimal side-effects [67] . In some, improvement was maintained up to 1 yr after treatment.
Following direct UV-Ai phototherapy of patients with SLE and SCLE, without a chromophore, photosensitive skin lesions, constitutional symptoms and arthritis improved with no activation of skin or systemic disease [11, 68] . Patients with anti-Ro/SSA antibodies appeared to have a greater response and no patient developed disease exacerbation. Improvement was maintained with decreased phototherapy sessions. Paradoxically, patients having photosensitive lesions, particularly SCLE, appeared to have the best response with either photopheresis or UV-Ai [11, 68] . SUMMARY Despite the prevalence of photosensitivity amongst lupus patients, light may be harnessed to benefit some patients. Unlike UV-B, UV-A has photobiological effects that may be beneficial. While we treat patients at present with potentially toxic medication, UV-A, and photopheresis appear to be safe therapies without exacerbation of skin or systemic disease. In fact, photopheresis appears to have no effect on normal cell-mediated immune function [63] . The notion of clinical improvement after UV-Ai treatment is provocative and contradictory to the maxim that light harms the SLE patient. The mechanism of this therapy is unclear, although UV-Ai does not affect LC function and therefore may not allow B-cell stimulation. Could repetitive irradiation with low-dose UV-A t result in decreased oxidative damage? Further laboratory investigation may clarify the mechanism by which light affects disease activity, while large, controlled clinical trials are needed to confirm the safety and efficacy of therapy, in which at last some forms of light are no longer a foe, but a friend to those with SLE.
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